blogspot visit counter
Navigation
World Time
New York City San Francisco London Paris / Frankfurt Tokyo HK / Shanghai Mumbai / Bangalore

RSS Feed:   Mobile: m.nextwaveresearch.com   Translate:

Sunday
20Dec2009

NovaBay (NBY): Interview with Dr. Bernard Churchill at UCLA Medical

DateSunday, December 20, 2009 at 06:00PM | by AuthorStephen M. Dunn

Dr. Bernard Churchill
Member of the Scientific Advisory Board for NovaBay PharmaceuticalsNovaBay Pharmaceuticals (Amex:NBY) has a world-renowned urologist on their Scientific Advisory Board, Dr. Bernard Churchill at UCLA Medical Center. In fact, the urology department at the UCLA Medical Center was ranked #4 in the nation (and best in California) by U.S. News & World Report. And in October, Dr. Churchill was awarded the Urology Medal by the American Academy of Pediatrics at their Annual Meeting in Washington DC. This is the most prestigious award given by the American Academy of Pediatrics Section of Urology which recognizes outstanding Career Contributions.

In this interview with Dr. Churchill, he discusses NovaBay's current Aganocide® program for Catheter-Associated Urinary Tract Infections (CAUTI) and how prevention and treatment for these infections, which can be fatal, have not materially improved in many years. We invite investors to listen as Dr. Churchill describes how NovaBay Pharmaceutical Aganocides® could represent a breakthough in the prevention of CAUTI. This is particularly important as Medicare and private insurance companies are no longer reimbursing hospitals for hospital-acquired CAUTI.

CLICK PLAY BELOW TO LISTEN (40 min.)

To Download MP3 File: Right-Click and Choose "Save Target As" (38MB)

Please see NBY Disclosures

See All ,
Print ArticlePRINT | | |
Wednesday
16Dec2009

NovaBay (NBY): Interview with the "Father of Biofilm Infections"

DateWednesday, December 16, 2009 at 04:09PM | by AuthorStephen M. Dunn

Dr. J. William Costerton
Member of the Scientific Advisory Board for NovaBay PharmaceuticalsNovaBay Pharmaceuticals (Amex:NBY) is extremely fortunate to have Dr. J. William Costerton on their Scientific Advisory Board. Dr. Costerton is the Father (or as he jokes, the Grandfather) of Biofilm infection research and is the world's leading authority on Biofilm microbiology. In this interview with Dr. Costerton, he discusses why Biofilms, representing up to 65% of all bacterial infections, are so difficult to kill. He also tells us why he believes NovaBay's Aganocide® compounds will show success in killing Biofilm infections without developing antibiotic-resistant bacterial strains. We invite investors to listen as Dr. Costerton describes how Biofilms play a role in all of NovaBay Pharmaceuticals development programs and why partners Alcon (NYSE:ACL) and Galderma S.A. are helping bring Aganocides® through human clinical trials as well as NovaBay's own internal development programs.

CLICK PLAY BELOW TO LISTEN (31 min.)

To Download MP3 File: Right-Click and Choose "Save Target As" (29MB)

Please see NBY Disclosures

See All ,
Print ArticlePRINT | | |
Wednesday
16Dec2009

Access Pharmaceuticals (ACCP): Initiating at STRONG SPECULATIVE BUY

DateWednesday, December 16, 2009 at 12:55PM | by AuthorStephen M. Dunn

CLICK TO DOWNLOAD FULL INITIATION REPORT

Access Pharmaceuticals MuGard™ is expected to launch in the United States in Q1 2010. MuGard™ is the first FDA-approved, ready-to-use, mucoadhesive oral wound rinse for oral mucositis (affecting an estimated 400,000 cancer patients in the U.S.). Access’ European partner has recently launched MuGard™ in the U.K, Germany, Italy, Norway, Greece and Sweden with additional EU launches expected.

Access Pharmaceuticals ProLindac™ is expected to begin Phase II human clinical trials in Europe and Asia in H1 2010.  ProLindac™ DACH-platinum candidate represents the next generation in this drug class. Sanofi Aventis’ (NYSE:SNY) Eloxatin® (oxaliplatin) had 2008 sales of approximately $1.9B. Access is planning Phase II trials in combination with Taxol® (paclitaxel) in recurrent ovarian cancer and liver and/or pancreatic cancer with Gemzar® (gemcitabine).

Access Pharmaceuticals Thiarabine™ (4'-thio-ara-C) is expected to initiate Phase IIa trials in adult cancer patients with Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma as early as Q1 2010. Other catalysts include US/EU partner proof-of-concept data for Cobalamin™ oral delivery with insulin and  hGH, a stock listing on the Nasdaq or Amex exchange and the sale of Pexiganon and EcoNail assets.

Although investors may wait until Access raises more capital to avoid shareholder dilution, experienced biotech investors are aware that occasionally the value of a promising company increases when it receives enough funding to reach the next milestones. We are initiating Access Pharmaceuticals with a Strong Speculative Buy and $7.00 Price Target.

Click to Download Full Initiation Report

Please see ACCP Disclosures

See All ,
Print ArticlePRINT | | |
Tuesday
15Dec2009

NovaBay Pharmaceuticals (NBY): Initiating at STRONG SPECULATIVE BUY

DateTuesday, December 15, 2009 at 06:00AM | by AuthorStephen M. Dunn

CLICK TO DOWNLOAD FULL INITIATION REPORT

We believe NovaBay Pharmaceuticals (Amex:NBY) represents a significant opportunity in the drug-resistant pathogen sector.  NovaBay’s Aganocide® compounds are proprietary, synthetic N-chlorinated antimicrobial molecules that mimic the human body’s natural antimicrobial defenses generated within neutrophils (white blood cells).  It is believed that bacteria cannot, or will not, develop resistance to these Aganocide® compounds. This is especially important as several strains of antibiotic-resistance bacteria have developed in humans such as MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant Enterococcus) which have resulted in patient deaths.  Aganocides® may deliver the same or better efficacy than antibiotics without triggering antibiotic-resistance.

We expect several catalysts for NovaBay shares as various human clinical trials complete. Phase IIa data for Conjunctivitis (“pink eye”) partnered with Alcon (NYSE:ACL), Phase I data for Acne partnered with Galderma S.A. (Nestle and L'Oreal) and Phase IIa data for Catheter-Associated Urinary Tract Infections (CAUTI) which is being developed internally. Furthermore, we expect data from the Phase IIa for Impetigo partnered with Galderma S.A.

In addition, we expect several new indications to begin human clinical trials with partner Alcon for Otitis Externa (swimmer's ear), Contact Lens Solution and Sinusitis (sinus infection) as well as NovaBay’s internal Onychomycosis (nail fungus) program.

We believe NovaBay is an exciting biotechnology company with “best-in-class” candidates that appear effective against bacterial, viral, fungal and biofilm targets without generating new, drug-resistant strains. NovaBay’s partnerships with Alcon (NYSE:ACL) and Galderma S.A. (Nestle and L'Oreal) along with NovaBay’s own internal programs result in a biotechnology company with multiple shots-on-goal. We are initiating research coverage with a Strong Speculative Buy rating and $4.50 Price Target.

Click to Download Full Initiation Report

Please see NBY Disclosures

See All ,
Print ArticlePRINT | | |
Tuesday
28Apr2009

Endologix (ELGX): Initiating Research Coverage with STRONG BUY

DateTuesday, April 28, 2009 at 07:00AM | by AuthorJohn M. Putnam, CFA

CLICK TO DOWNLOAD FULL INITIATION REPORTOver the past few months, Endologix has received four new product approvals from the U.S. Food and Drug Administration that open new segments of the Abdominal Aortic Aneurysm (AAA) market and improve the ease-of-use of its entire product portfolio. The company is financially strong and on the verge of becoming operating cash flow positive in the current quarter and profitable by the end of 2009 or early in 2010. Endologix's products address a large and growing market. The world-wide market is over $700 million and is growing at 9% CAGR. Aortic Aneurysms are age related with over 2 million older Americans affected and 200,000 new cases diagnosed annually, resulting in approximately 60,000 procedures being performed each year. The treatment of an AAA is not elective and is therefore immune to economic conditions. At some stage, the aneurysm becomes too large to be ignored and requires immediate attention or a rupture and almost certain death will occur. We are initiating research coverage on Endologix (ELGX) with a Strong Buy Rating and a $4.50 Price Target based on the stock selling at 3.0X its projected 2010 revenues of $65.0 million, discounted at 10%.

Click to Download Full Initiation Report

Please see ELGX Disclosures

See All ,
Print ArticlePRINT | | |
Page 1 2 3 4 ... 4 Next 5 Entries ยป